Please use landscape view or desktop screen to view the content.
Tafamidis
(VYNDAQEL
®
/ VYNDAMAX
®
)
Clinical Overview
Study Overview
Study Design
Patient Enrollment
Inclusion and Exclusion Criteria
Baseline Demographics
Study Endpoints
Primary Endpoints
All-Cause Mortality
CV-Related Hospitalizations
Secondary Endpoints
6MWT
KCCQ-OS
Results
Conclusions and Summary
Additional Analysis
Bioequivalence of VYNDAQEL/VYNDAMAX
Long–term Analysis
